Cargando…

Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand

INTRODUCTION: Chronic kidney disease (CKD) creates a significant economic burden on patients and society. The DAPA-CKD trial reports the benefit of dapagliflozin in CKD patients; however, its cost-effectiveness is unknown in Thailand. This study evaluated the cost–utility of dapagliflozin in additio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vareesangthip, Kriengsak, Deerochanawong, Chaicharn, Thongsuk, Dittaya, Pojchaijongdee, Nuch, Permsuwan, Unchalee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918172/ https://www.ncbi.nlm.nih.gov/pubmed/35038121 http://dx.doi.org/10.1007/s12325-021-02037-6

Ejemplares similares

Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2021)

Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2023)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Treatment Costs for Patients with Chronic Kidney Disease Who Received Multidisciplinary Care in a District Hospital in Thailand
por: Songsermlosakul, Suwaporn, et al.
Publicado: (2020)

Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2020)

Diabetes management in Thailand: a literature review of the burden, costs, and outcomes
por: Deerochanawong, Chaicharn, et al.
Publicado: (2013)

Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
por: Yamwong, Sukit, et al.
Publicado: (2014)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2016)

Economic Burdens of Type 2 Diabetes Hospital Visits with Hypoglycemic Episodes in the Tertiary Care Setting in Thailand
por: Kosachunhanun, Natapong, et al.
Publicado: (2023)

Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study
por: Phrommintikul, Arintaya, et al.
Publicado: (2022)

Cost–Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand
por: Permsuwan, Unchalee, et al.
Publicado: (2022)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Discounting money and health effects from communicable and noncommunicable diseases in Thailand
por: Yadee, Jirawit, et al.
Publicado: (2023)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database
por: Suwankesawong, Wimon, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
por: Krittayaphong, Rungroj, et al.
Publicado: (2019)

Prevalence of chronic kidney disease in Thai adults: a national health survey
por: Ong-ajyooth, Leena, et al.
Publicado: (2009)

Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand
por: Chawalitmongkol, Korawan, et al.
Publicado: (2023)

Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study
por: Deerochanawong, Chaicharn, et al.
Publicado: (2020)

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
por: Sriuttha, Pajaree, et al.
Publicado: (2018)

Prevalence of the MDR1 gene mutation in herding dog breeds and Thai Ridgebacks in Thailand
por: Lerdkrai, Chommanad, et al.
Publicado: (2021)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

A novel multiplex polymerase chain reaction assay for the genotypic survey of the non-homologous end-joining factor 1 gene associated with Collie eye anomaly in Thailand
por: Lerdkrai, Chommanad, et al.
Publicado: (2022)

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
por: Liao, Chia-Te, et al.
Publicado: (2021)

Cost-utility analysis of repetitive transcranial magnetic stimulation as add-on therapy to standard care for the treatment of hallucinations in schizophrenia
por: Hendriks, Lauren, et al.
Publicado: (2022)

Factors Associated with Depression, Anxiety, and Somatic Symptoms among International Salespeople in the Medical Device Industry: A Cross-Sectional Study in China
por: Mao, Beibei, et al.
Publicado: (2023)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population
por: Al AdAwi, Rana Moustafa, et al.
Publicado: (2019)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
por: Benjamin, Silas, et al.
Publicado: (2021)

Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease
por: Assanatham, Montira, et al.
Publicado: (2022)

Dapagliflozin in patients with COVID-19: mind the kidneys
por: Reis, Thiago, et al.
Publicado: (2022)

SAT-612 An Anti-Idiotype Antibody to T3 Measurements: A Misleading Cause of Inappropriate TSH Secretion
por: Treesaranuwattana, Thitinan, et al.
Publicado: (2019)

Novel and de novo PKD1 mutations identified by multiple restriction fragment-single strand conformation polymorphism (MRF-SSCP)
por: Thongnoppakhun, Wanna, et al.
Publicado: (2004)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_be7h7v51uq0t32ag7l7f16t6ea